Home › Companies › Benitec Biopharma Inc. › 2025-2026
At Benitec Biopharma Inc.'s shareholder meeting held December 1, 2025, in the 2025-2026 proxy season, 76 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 366 separate fund positions. On the most widely held item on that ballot — Approval of the non-binding advisory vote on the compensation of the Company's named executive… — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Benitec Biopharma Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on December 2, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Benitec Biopharma Inc.’s Form 8-K, filed December 2, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of December 1, 2025: 4 items on Benitec Biopharma Inc.’s Form 8-K, filed December 2, 2025: 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Benitec Biopharma Inc. in the interactive database Compare manager voting policies
These tallies are Benitec Biopharma Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed December 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Jerel Banks | 22,150,169 | -- | -- | 101,379 | 76,213 | 99.5% | Not verified | — |
| Elect Director: Megan Boston | 21,693,741 | -- | -- | 557,807 | 76,213 | 97% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 22,252,834 | 4,787 | 70,140 | -- | -- | 99.9% | Not verified | — |
| 3. Advisory Vote on Executive Compensation | 17,239,339 | 4,939,686 | 72,523 | -- | 76,213 | 78% | Not verified | — |
Source: Benitec Biopharma Inc., Form 8-K, filed with the SEC on December 2, 2025 — read the filing on EDGAR.
Each item below shows how the 76 asset managers that disclosed a Benitec Biopharma Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Class III: Dr. Jerel Banks
Benitec Biopharma Inc.’s own tally for this item (“Elect Director: Dr. Jerel Banks”): 22,150,169 for, 101,379 withheld, per its Form 8-K filed December 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 32 asset managers below reported 2,744,750 for, 4,340 withheld, 320 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 993,252 | 0 | 0 | 0 | For |
| Vanguard | 845,845 | 0 | 0 | 0 | For |
| BlackRock | 379,424 | 0 | 0 | 0 | For |
| Fidelity | 291,434 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 79,521 | 0 | 0 | 0 | For |
| Charles Schwab | 45,274 | 0 | 0 | 0 | For |
| Equitable | 25,959 | 0 | 0 | 0 | For |
| Goldman Sachs | 14,102 | 0 | 0 | 0 | For |
| Lincoln Financial | 11,300 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 7,529 | 0 | 0 | 0 | For |
| Global X | 6,763 | 0 | 0 | 0 | For |
| Northern Trust | 6,185 | 0 | 0 | 0 | For |
| Brighthouse | 5,673 | 0 | 0 | 0 | For |
| State Street | 4,259 | 0 | 0 | 0 | For |
| Pacific Life | 4,245 | 0 | 0 | 0 | For |
| Nationwide | 3,943 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,883 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 2,863 | Withhold |
| Victory Capital | 2,819 | 0 | 0 | 0 | For |
| ProShares | 2,803 | 0 | 0 | 0 | For |
| DWS | 2,214 | 0 | 0 | 0 | For |
| SEI | 1,180 | 0 | 320 | 0 | Mixed |
| Calvert | 0 | 0 | 0 | 1,477 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 1,469 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,363 | 0 | 0 | 0 | For |
Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Class III: Megan Boston
Benitec Biopharma Inc.’s own tally for this item (“Elect Director: Megan Boston”): 21,693,741 for, 557,807 withheld, per its Form 8-K filed December 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 32 asset managers below reported 2,724,595 for, 23,315 withheld, 1,500 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 993,252 | 0 | 0 | 0 | For |
| Vanguard | 845,845 | 0 | 0 | 0 | For |
| BlackRock | 379,424 | 0 | 0 | 0 | For |
| Fidelity | 291,434 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 79,521 | 0 | 0 | 0 | For |
| Charles Schwab | 45,274 | 0 | 0 | 0 | For |
| Equitable | 25,959 | 0 | 0 | 0 | For |
| Goldman Sachs | 14,102 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 11,300 | Withhold |
| AIG/SunAmerica | 7,529 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 6,763 | Withhold |
| Northern Trust | 6,185 | 0 | 0 | 0 | For |
| Brighthouse | 5,673 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 4,259 | Withhold |
| Pacific Life | 4,245 | 0 | 0 | 0 | For |
| Nationwide | 3,943 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,883 | 0 | 0 | 0 | For |
| Voya | 2,863 | 0 | 0 | 0 | For |
| Victory Capital | 2,819 | 0 | 0 | 0 | For |
| ProShares | 2,803 | 0 | 0 | 0 | For |
| DWS | 2,214 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 1,500 | 0 | Abstain |
| Calvert | 1,477 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 1,469 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,363 | 0 | 0 | 0 | For |
Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: Approval of the non-binding advisory vote on the compensation of the Company's named executive officers as disclosed in the attached proxy statement.
Benitec Biopharma Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 17,239,339 for, 4,939,686 against, per its Form 8-K filed December 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 993,252 | 0 | 0 | 0 | For |
| Vanguard | 0 | 845,845 | 0 | 0 | Against |
| BlackRock | 0 | 379,424 | 0 | 0 | Against |
| Fidelity | 0 | 291,434 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 79,521 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 45,274 | 0 | 0 | Against |
| Equitable | 0 | 25,959 | 0 | 0 | Against |
| Goldman Sachs | 0 | 14,102 | 0 | 0 | Against |
| Lincoln Financial | 0 | 11,300 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 7,529 | 0 | 0 | Against |
| Global X | 0 | 6,763 | 0 | 0 | Against |
| Northern Trust | 6,185 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 5,673 | 0 | 0 | Against |
| State Street | 0 | 4,259 | 0 | 0 | Against |
| Pacific Life | 0 | 4,245 | 0 | 0 | Against |
| Nationwide | 0 | 3,943 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 2,883 | 0 | 0 | Against |
| Voya | 0 | 2,863 | 0 | 0 | Against |
| Victory Capital | 0 | 2,819 | 0 | 0 | Against |
| ProShares | 0 | 2,803 | 0 | 0 | Against |
| DWS | 0 | 2,214 | 0 | 0 | Against |
| SEI | 0 | 1,500 | 0 | 0 | Against |
| Calvert | 0 | 1,477 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 1,469 | 0 | 0 | Against |
| T. Rowe Price | 0 | 1,363 | 0 | 0 | Against |
Fund voting reports, all 32 managers: 1,078,958 for, 1,670,452 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 9,647,827 | 0 | 0 | 0 | For |
| Janus Henderson | 5,404,316 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,195,387 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 1,972,524 | 0 | 0 | Against |
| Nantahala Capital Management, LLC | 546,824 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 353,505 | 0 | 0 | Against |
| Logos Global Management LP | 0 | 350,000 | 0 | 0 | Against |
| BlackRock | 1,550 | 273,774 | 0 | 0 | Against |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 163,754 | 0 | 0 | Against |
| AMERIPRISE FINANCIAL INC | 0 | 158,016 | 0 | 0 | Against |
| Northern Trust | 88,289 | 3,298 | 0 | 0 | For |
| State Street | 0 | 83,797 | 0 | 0 | Against |
| Charles Schwab | 0 | 45,274 | 0 | 0 | Against |
| Vanguard | 0 | 44,944 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 25,143 | 0 | 0 | Against |
| T. Rowe Price | 0 | 14,554 | 0 | 0 | Against |
| Invesco | 0 | 7,113 | 0 | 0 | Against |
| JPMorgan | 5,989 | 0 | 0 | 0 | For |
| Rhumbline | 0 | 5,441 | 0 | 0 | Against |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 4,327 | 0 | 0 | Against |
| MetLife Investment Management, LLC | 0 | 3,724 | 0 | 0 | Against |
| BANK OF AMERICA NA | 0 | 3,028 | 0 | 0 | Against |
| Voya | 0 | 2,863 | 0 | 0 | Against |
| Victory Capital | 0 | 2,819 | 0 | 0 | Against |
| Goldman Sachs | 0 | 2,538 | 0 | 0 | Against |
Institutional-manager reports, all 57 managers: 17,897,041 for, 3,542,805 against. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026.
Benitec Biopharma Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 22,252,834 for, 4,787 against, per its Form 8-K filed December 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 32 asset managers below reported 2,749,410 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 993,252 | 0 | 0 | 0 | For |
| Vanguard | 845,845 | 0 | 0 | 0 | For |
| BlackRock | 379,424 | 0 | 0 | 0 | For |
| Fidelity | 291,434 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 79,521 | 0 | 0 | 0 | For |
| Charles Schwab | 45,274 | 0 | 0 | 0 | For |
| Equitable | 25,959 | 0 | 0 | 0 | For |
| Goldman Sachs | 14,102 | 0 | 0 | 0 | For |
| Lincoln Financial | 11,300 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 7,529 | 0 | 0 | 0 | For |
| Global X | 6,763 | 0 | 0 | 0 | For |
| Northern Trust | 6,185 | 0 | 0 | 0 | For |
| Brighthouse | 5,673 | 0 | 0 | 0 | For |
| State Street | 4,259 | 0 | 0 | 0 | For |
| Pacific Life | 4,245 | 0 | 0 | 0 | For |
| Nationwide | 3,943 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,883 | 0 | 0 | 0 | For |
| Voya | 2,863 | 0 | 0 | 0 | For |
| Victory Capital | 2,819 | 0 | 0 | 0 | For |
| ProShares | 2,803 | 0 | 0 | 0 | For |
| DWS | 2,214 | 0 | 0 | 0 | For |
| SEI | 1,500 | 0 | 0 | 0 | For |
| Calvert | 1,477 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 1,469 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,363 | 0 | 0 | 0 | For |
Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 33,862,226 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FRANKLIN STRATEGIC SERIES | 2.93% |
| 2 | Vanguard | 2.50% |
| 3 | BlackRock | 1.12% |
| 4 | Fidelity | 0.86% |
| 5 | Simplify Exchange Traded Funds | 0.23% |
| 6 | Charles Schwab | 0.13% |
| 7 | Equitable | 0.08% |
| 8 | Goldman Sachs | 0.04% |
| 9 | Lincoln Financial | 0.03% |
| 10 | AIG/SunAmerica | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 28.49% |
| 2 | Janus Henderson | 15.96% |
| 3 | FRANKLIN ADVISERS INC | 6.48% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.83% |
| 5 | Nantahala Capital Management, LLC | 1.61% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.04% |
| 7 | Logos Global Management LP | 1.03% |
| 8 | BlackRock | 0.81% |
| 9 | SILVERARC CAPITAL MANAGEMENT, LLC | 0.48% |
| 10 | AMERIPRISE FINANCIAL INC | 0.47% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Franklin Resources, Inc. | 11.08% | 13G |
| Franklin Templeton | 7.02% | 13F |
| BlackRock | 3.50% | 13F |
| Vanguard Group | 3.47% | 13F |
| Millennium Management | 1.93% | 13F |
| Geode Capital | 1.55% | 13F |
| State Street | 1.00% | 13F |
| Goldman Sachs | 0.64% | 13F |
| Citadel Advisors | 0.51% | 13F |
| Northern Trust | 0.46% | 13F |
Percentages above are of 33,862,226 shares outstanding, as reported by Benitec Biopharma Inc. on its Form 10-Q dated November 14, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Benitec Biopharma Inc.’s 10-Q dated November 14, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Benitec Biopharma Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Benitec Biopharma (BNTC) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/benitec-biopharma-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.